Aclaris Therapeutics, Inc.（ACRS）の財務ACRSAclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. (ACRS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Licensing, accounting for 78.1% of total sales, equivalent to $1.27M. Another important revenue stream is Laboratory Research Revenue. Understanding this composition is critical for investors evaluating how ACRS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Aclaris Therapeutics, Inc. maintains a gross margin of 10.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1469.49%, while the net margin is -1320.14%. These profitability ratios, combined with a Return on Equity (ROE) of -59.10%, provide a clear picture of how effectively ACRS converts its operational activities into shareholder value.

In the context of the broader market, ACRS competes directly with industry leaders such as AQST and DBVT. With a market capitalization of $554.94M, it holds a significant position in the sector. When comparing efficiency, ACRS's gross margin of 10.80% stands against AQST's 70.93% and DBVT's 100.00%. Such benchmarking helps identify whether Aclaris Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Aclaris reported a Q2 GAAP EPS of -$0.15, beating expectations slightly, and has shown a gross margin improvement to 10.80% in Q2 2026, up from negative margins in previous quarters, suggesting a potential turnaround in profitability.